New Delhi: Shortly after Drugs Controller General of India (DCGI) cleared its Covishield vaccine for emergency approval in the country, CEO of Serum Institute of India, Adar Poonawalla, took to Twitter and said “all the risks SerumInstIndia took with stockpiling the vaccine, have finally paid off.”
He said ‘Covishield’ vaccine, developed by Serum Institute of India in partnership with the Oxford University and pharma major AstraZeneca, is “safe and effective” against coronavirus and added that the vaccine “is ready to roll out in the coming weeks”.
<>
Happy new year, everyone! All the risks @SerumInstIndia took with stockpiling the vaccine, have finally paid off. COVISHIELD, India’s first COVID-19 vaccine is approved, safe, effective and ready to roll-out in the coming weeks. pic.twitter.com/TcKh4bZIKK
— Adar Poonawalla (@adarpoonawalla) January 3, 2021
</>
Apart from Covishield, Bharat Biotech’s Covaxin has been granted permission for “restricted use”.
Serum Institute of India’s Covishield was the first vaccine to be recommended for “restricted use” by the the government-appointed panel on Friday. Covaxin, the coronavirus vaccine from Hyderabad-based Bharat Biotech, was recommended a day later, on Saturday.
